Longitudinal assessment of oxaliplatininduced neuropathy

Neurology

Volumn 77, Issue 10, 2011, Pages 980-986

  Burakgazi, A Z ^a   Messersmith, W ^a   Vaidya, D ^a   Hauer, P ^a   Hoke, A ^a   Polydefkis, M ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM; FLUOROURACIL; FOLINIC ACID; MAGNESIUM; OXALIPLATIN; ANTINEOPLASTIC AGENT; PLATINUM COMPLEX;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CLINICAL ARTICLE; CLINICAL TRIAL; COLON CANCER; COLORECTAL CANCER; CONTINUOUS INFUSION; FEMALE; HUMAN; HUMAN TISSUE; INTRAEPIDERMAL NERVE FIBER DENSITY; LARYNX DISORDER; MALE; MULTIPLE CYCLE TREATMENT; NERVE CONDUCTION; NERVOUS SYSTEM PARAMETERS; NEUROPATHY; OXALIPLATIN ASSOCIATED NEUROPATHY; PARESTHESIA; PRIORITY JOURNAL; PROSPECTIVE STUDY; SKIN TINGLING; TRANSCUTANEOUS NERVE STIMULATION; CHEMICALLY INDUCED DISORDER; COLORECTAL TUMOR; COMPARATIVE STUDY; LONGITUDINAL STUDY; MIDDLE AGED; PATHOPHYSIOLOGY; POLYNEUROPATHY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; COLORECTAL NEOPLASMS; FEMALE; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; ORGANOPLATINUM COMPOUNDS; POLYNEUROPATHIES; PROSPECTIVE STUDIES;

EID: 80055075334     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e31822cfc59     Document Type: Article

References (21)

1. Cersosimo RJ. Oxaliplatin-associated neuropathy: a review. Ann Pharmacother 2005;39:128-135. (Pubitemid 40052388)
2. Gamelin E, Gamelin L, Bossi L, Quasthoff S. Clinical aspects and molecular basis of oxaliplatin neurotoxicity: current management and development of preventive measures. Semin Oncol 2002;29:21-33. (Pubitemid 35191038)
3. Diaz-Rubio E, Sastre J, Zaniboni A, et al. Oxaliplatin as single agent in previously untreated colorectal carcinoma patients: a phase II multicentric study. Ann Oncol 1998;9: 105-108. (Pubitemid 28125772)
4. Machover D, Diaz-Rubio E, de Gramont A, et al. Two consecutive phase II studies of oxaliplatin (L-OHP) for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidines. Ann Oncol 1996;7:95-98. (Pubitemid 26051870)
5. Becouarn Y, Ychou M, Ducreux M, et al. Phase II trial of oxaliplatin as first-line chemotherapy in metastatic colorectal cancer patients: Digestive Group of French Federation of Cancer Centers. J Clin Oncol 1998;16:2739-2744. (Pubitemid 28363039)
6. Tournigand C, Cervantes A, Figer A, et al. OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-Go fashion in advanced colorectal cancer: a GERCOR study. J Clin Oncol 2006;24:394-400. (Pubitemid 46630458)
7. Chibaudel B, Maindrault-Goebel F, Lledo G, et al. Can chemotherapy be discontinued in unresectable metastatic colorectal cancer? The GERCOR OPTIMOX2 Study. J Clin Oncol 2009;27:5727-5733.
8. Andre T, Bensmaine MA, Louvet C, et al. Multicenter phase II study of bimonthly high-dose leucovorin, fluorouracil infusion, and oxaliplatin for metastatic colorectal cancer resistant to the same leucovorin and fluorouracil regimen. J Clin Oncol 1999;17:3560-3568. (Pubitemid 29517928)
9. Wilson RH, Lehky T, Thomas RR, Quinn MG, Floeter MK, Grem JL. Acute oxaliplatin-induced peripheral nerve hyperexcitability. J Clin Oncol 2002;20:1767-1774. (Pubitemid 34273265)
10. Chaudhry V, Rowinsky EK, Sartorius SE, Donehower RC, Cornblath DR. Peripheral neuropathy from Taxol and cisplatin combination chemotherapy: clinical and electrophysiological studies. Ann Neurol 1994;35:304-311. (Pubitemid 24089653)
11. Chaudhry V, Eisenberger MA, Sinibaldi VJ, Sheikh K, Griffin JW, Cornblath DR. A prospective study of suramin-induced peripheral neuropathy. Brain 1996;119: 2039-2052. (Pubitemid 27032634)
12. Cavaletti G, Bogliun G, Marzorati L, et al. Grading of chemotherapy-induced peripheral neurotoxicity using the Total Neuropathy Scale. Neurology 2003;61:1297-1300. (Pubitemid 37377562)
13. Holland NR, Crawford TO, Hauer P, Cornblath DR, Griffin JW, McArthur JC. Small-fiber sensory neuropathies: clinical course and neuropathology of idiopathic cases. Ann Neurol 1998;44:47-59. (Pubitemid 28323654)
14. McArthur JC, Stocks EA, Hauer P, Cornblath DR, Griffin JW. Epidermal nerve fiber density: normative reference range and diagnostic efficiency. Arch Neurol 1998;55: 1513-1520.
15. Cavaletti G, Jann S, Pace A, et al. Multi-center assessment of the Total Neuropathy Score for chemotherapy-induced peripheral neurotoxicity. J Peripher Nerv Syst 2006;11: 135-141. (Pubitemid 43894080)
16. Lauria G, Sghirlanzoni A, Lombardi R, Pareyson D. Epidermal nerve fiber density in sensory ganglionopathies: clinical and neurophysiologic correlations. Muscle Nerve 2001;24:1034-1039. (Pubitemid 32656189)
17. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981;47:207-214. (Pubitemid 11167383)
18. de Gramont A, Figer A, Seymour M, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000;18: 2938-2947. (Pubitemid 30644117)
19. Nunez F, Vranceanu AM, Ring D. Determinants of pain in patients with carpal tunnel syndrome. Clin Orthop Relat Res 2010;468:3328-3332.
20. Postma TJ, Heimans JJ, Muller MJ, Ossenkoppele GJ, Vermorken JB, Aaronson NK. Pitfalls in grading severity of chemotherapy-induced peripheral neuropathy. Ann Oncol 1998;9:739-744. (Pubitemid 28394160)
21. Dyck PJ, Overland CJ, Low PA, et al. Signs and symptoms versus nerve conduction studies to diagnose diabetic sensorimotor polyneuropathy: Cl vs. NPhys trial. Muscle Nerve 2010;42:157-164.